Clinical aspects of tuberculosis pleurisy in patients with cancer of various localizations
https://doi.org/10.21292/2075-1230-2020-98-2-35-40
Abstract
The objective of the study is to determine characteristics of the clinical course and treatment results of tuberculosis exudative pleurisy in patients with cancer of various localizations.
Subjects and methods. Case histories of 26 patients aged 42-83 years (18 men, 8 women) with tuberculosis exudative pleurisy and concurrent cancer of various localization treated in 1985-2016 were analyzed. Those patients were compared to the group of 120 patients with tuberculosis exudative pleurisy but no concurrent cancer.
Results: From 1985 to 2016, 26 (0.95%) of the 2,723 tuberculosis exudative pleurisy patients suffered from concurrent cancer of various localizations. 10/26 (38.46%) cancer patients were diagnosed 1-13 years before tuberculosis exudative pleurisy developed, all of them received combination anticancer therapy. Other risk factors of developing tuberculosis in patients with tuberculosis exudative pleurisy and cancer of various localizations were the following: exposure to a tuberculosis case (15%), residual changes after previous tuberculosis (38.5%), elderly and senile age (61.5%), and comorbidities (77%). The treatment effectiveness of tuberculosis exudative pleurisy in them was lower compared to the patients without cancer: cure with minimal pleural overlays was less frequent (p1-2 < 0.05; χ2); pleural exudation persisted for a longer period of time (p1-2 < 0.01; χ2); the serous exudate transferred into purulent one more often(p1-2 < 0.05; χ2).
About the Author
N. A. Stogova
Voronezh State Medical University named after N.N. Burdenko
Russian Federation
Russian Federation
Professor of Phthisiology Department
10, Studencheskaya St., Voronezh, 394036
Phone: +7 (473) 237-28-53
References
1. Erokhin V.V., Romanova L.K. Kletochnaya biologiya lyogkikh v norme i pri patologii. Rukovodstvo dlya vrachey. [Cellular biology of the lungs in health and pathology. Nephrology. Doctors' guidelines]. Moscow, Meditsina Publ., 2000, 496 p.
2. Kaprin А.D., Starinskiy V.V., Petrova G.V. Zlokachestvennye novoobrazovaniya v Rossii v 2017 g. [Malicious tumors in Russia in 2017]. Moscow, MNIOI Im. P. А. Gertsena – Filial FGBU NMITS Radiologii Minzdrava Rossii Publ., 2018, 250 p.
3. Koretskaya N.M., Lesunova I.V. Clinical signs and diagnosis of lung cancer in elderly and senile age with residual tuberculosis changes. Uspekhi Gerontologii, 2011, vol. 24, no. 3, pp. 456-459. (In Russ.)
4. Çakar B., Çiledağ A. Evaluation of coexistence of cancer and active tuberculosis; 16 case series. Respir. Med. Case Rep., 2017, vol. 20, no. 23, pp. 33-37.
5. Cegla P., Spychala A., Marszalek A., Wierzchoslawska E., Cholewinski W. Atypical spleen tuberculosis in a melanoma patient accidentally detected during a 18F-FDG PET/CT study: Case report. Mol. Clin. Oncol., 2018, vol. 8, no. 1, pp. 89-92.
6. Chaabouni H., Féki J., Elleuch E., Charfi S., Khanfir A., Toumi N., Boudawara T., Ben Jmea M., Daoud J., Frikha M. Tuberculosis and non-pulmonary malignancies: study of ten cases. Tunis Med., 2018, vol. 96, no. 6, pp. 343-347.
7. Dobler C.C. Cumulative incidence and incidence rate ratio for estimation of risk of tuberculosis in patients with cancer. Clin. Infect. Dis., 2017, vol. 65, no. 8, pp. 1423-1424.
8. Jacobs R.E., Gu P., Chachoua A. Reactivation of pulmonary tuberculosis during cancer treatment. Int. J. Mycobacteriol., 2015, vol. 4, no. 4, pp. 337-340.
9. Lee J., Lee Y.D., Lim J.K., Lee D.H., Yoo S.S., Lee S.Y., Cha S.I., Park J.Y., Kim C.H. Predictive factors and treatment outcomes of tuberculous pleural effusion in patients with cancer and pleural effusion. Am. J. Med. Sci., 2017, vol. 354, no. 2, pp. 125-130.
10. Simonsen D.F., Farkas D.K., Horsburgh C.R., Thomsen R.W., Sørensen H.T. Increased risk of active tuberculosis after cancer diagnosis. J. Infect., 2017, vol. 74, no. 6, pp. 590-598.
11. Simonsen D.F., Farkas D.K., Søgaard M., Horsburgh C.R., Sørensen H.T., Thomsen R.W. Tuberculosis and risk of cancer: a Danish nationwide cohort study. Int. J. Tuberc. Lung Dis., 2014, vol. 18, no. 10, pp. 1211-1219.
12. Suzuki Y., Imokawa S., Sato J., Uto T., Suda T. Cumulative incidence of tuberculosis in lung cancer patients in Japan: A 6-year observational study. Respir. Investig., 2016, vol. 54, no. 3, pp. 179-183.
13. Thomas P., Foley R., Kosowicz L. Reativation of pulmonary tuberculosis following local radiation therapy of prostate cancer. Conn. Med., 2014, vol. 78, no. 2, pp. 77-80.
14. Wu L., Li M., Liu D., Jiang M., Liu Y., Li Z., Wang X., Yu Y., Luo F. Treatment of nasopharyngeal carcinoma with pulmonary tuberculosis and gout: A case report. Oncol. Lett., 2014, vol. 8, no. 2, pp. 753-757.
15. Yeon S-J., Young H-Y., Lee N-R., Song E-K., Kwak J-Y., Yim C-Y. Everolimus-induced activation of latent Mycobacterium tuberculosis infection in a patient with metastatic renal cell carcinoma. Korean J. Intern. Med., 2017, vol. 32, no. 2, pp. 365-368.
16. Yuba T., Hatsuse M., Kodama M., Uda S., Yoshimura A., Kurisu N. Reactivation of tuberculosis presenting with empyema due to anticancer chemotherapy for diffuse large b-cell lymphoma. Kekkaku, 2016, vol. 91, no. 4, pp. 475-479.
Review
For citations:
Stogova N.A. Clinical aspects of tuberculosis pleurisy in patients with cancer of various localizations. Tuberculosis and Lung Diseases. 2020;98(2):35-40. (In Russ.) https://doi.org/10.21292/2075-1230-2020-98-2-35-40
Views:
738
Email this article 